Lim Bryant David 4

What Happened Lim Bryant David, who serves as Chief Legal Officer, Chief Financial Officer and Corporate Secretary of Prelude Therapeutics (PRLD), received a derivative award on Feb 4, 2026 covering 275,000 shares. The Form 4 reports the acquisition as an award/derivative (code A) at $0.00 per share (reported value $0). This is a grant of equity-linked compensation (not a cash purchase or sale).

Key Details

• Transaction date: 2026-02-04; Form 4 filed: 2026-02-05 (Accession: 0001752888-26-000002).
• Instrument: Award/derivative covering 275,000 shares; reported acquisition price $0.00; total reported value $0.
• Vesting: 25% vests on Feb 4, 2027, then 1/48 of the total shares vests monthly thereafter until fully vested (requires continued service on each vesting date).
• Shares owned after transaction: Not specified in the provided filing details.
• Filing timeliness: No late filing flag provided in the supplied data.

Context This is an equity award (likely stock options or restricted stock units) that vests over time and does not represent immediately tradable shares. Such grants compensate and retain executives; they do not necessarily indicate immediate buying or selling by the insider. For investors, the key facts are the grant size and the multi-year vesting schedule — monitor future filings for exercises, sales, or additional disclosures.